Pharmaceutical

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.

Sep 7, 2023 - 20:00
Apollo Therapeutics secures $226.5m to advance pipeline programmes
Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round to advance its pipeline of programmes.
Read the original article

Tags:

Previous Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Next Article

Signal: Nimbus raises $210m to foster drug discovery plans

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem

J&J jumps on ADC train, signs $1.7bn licensing deal wit...

Dec 28, 2023

Navigating post-approval research and reimbursement for orphan therapies

Navigating post-approval research and reimbursement for...

Apr 9, 2024

Tapping into digital therapeutics to improve neurological outcomes

Tapping into digital therapeutics to improve neurologic...

Mar 19, 2023